Ergomed plc Exercise of Options & Issue of Equity (8557O)
February 01 2019 - 6:31AM
UK Regulatory
TIDMERGO
RNS Number : 8557O
Ergomed plc
01 February 2019
PRESS RELEASE
FOR IMMEDIATE RELEASE
Exercise of Options and Issue of Equity
Guildford, UK - 1 February 2019: Ergomed plc (LSE: ERGO)
('Ergomed' or 'the Company'), a company focused on providing
specialised services to the pharmaceutical industry, has issued and
allotted 1,000,000 new ordinary shares of 1p each in the Company
("New Ordinary Shares") following the exercise by a former employee
of options awarded under the Company's Unapproved Executive Share
Option Scheme 2007.
Accordingly, an application has been made for the 1,000,000 New
Ordinary Shares to be admitted to trading on AIM ('Admission'). It
is expected that Admission will occur at 8:00 a.m. on 5 February
2019. The New Ordinary Shares will rank pari passu with the
existing ordinary shares in the Company.
Following Admission, the Company's enlarged issued share capital
will comprise 46,016,438 ordinary shares with one voting right per
share. No shares are held in Treasury. The total number of voting
rights in the Company is therefore 46,016,438.
This figure of 46,016,438 ordinary shares may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure and Transparency Rules.
- Ends -
Enquiries:
Ergomed plc Tel: +44 (0) 1483 503205
Dr Miroslav Reljanovic (Executive Chairman)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEEAFAFEDENEFF
(END) Dow Jones Newswires
February 01, 2019 06:31 ET (11:31 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024